Drug-induced Parkinson's disease

Neurosciences

Volumn 18, Issue 3, 2013, Pages 215-221

  Bohlega, Saeed A ^a   Al Foghom, Nurah B ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIEMETIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CINNARIZINE; CLEBOPRIDE; DOMPERIDONE; DOPAMINE 2 RECEPTOR; FLUNARIZINE; HALOPERIDOL; METOCLOPRAMIDE; NEUROLEPTIC AGENT; OLANZAPINE; PIMOZIDE; QUETIAPINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; RISPERIDONE; SEROTONIN 2A RECEPTOR; UBIDECARENONE; VALPROIC ACID;

AGE; AKATHISIA; BRADYKINESIA; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; DISEASE PREDISPOSITION; DRUG MEGADOSE; DRUG USE; GENETIC PREDISPOSITION; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LOW DRUG DOSE; NEUROPROTECTION; NEUROTOXICITY; PARKINSONISM; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR; SMOKING; TARDIVE DYSKINESIA; TREMOR;

EID: 84906997442     PISSN: 13196138     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Micheli F, Cersosimo MG. Drug-induced parkinsonism. Handb Clin Neurol 2007; 84: 399-416.
2. Tanvi B, Treadwell S. Drug induced parkinsonism: a common cause of parkinsonism in older people. Postgrad Med J 2009; 85: 322-326.
3. Hae-Won Shin, Sun Ju Chung. Drug-Induced Parkinsonism. J Clin Neurol 2012; 8: 15-21.
4. Barbosa MT, Caramelli P, Maia D P, Cunningham MCQ, Guerra HL, Lima-Costa M F, et al. Parkinsonism and Parkinson's disease in the elderly: a community-based survey in Brazil (the Bambú study). Mov Disord 2006; 21: 800-808.
5. Jiménez-Jiménez FJ, Ortí-Pareja M, Ayuso-Peralta L, Gasalla T, Cabrera-Valdivia F, Vaquero A, et al. Drug-induced Parkinsonism in a Movement Disorders Unit: a four-year survey. Parkinsonism Relat Disord 1996; 2: 145-149.
6. Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990. Neurology 1999; 52: 1214-1220.
7. Friedman JH, Trieschmann ME, Fernandez HH. Drug-induced parkinsonism. In: Factor S. Lang AE, Weiner WJ, editors. Drug induced movement disorders. 2nd ed. New York (NY): Blackwell Futura; 2005. p. 103-109.
8. Rochon PA, Stukel TA, Sykora K, Gill S, Garfnkel S, Anderson GM, et al. Atypical antipsychotics and parkinsonism. Arch Intern Med 2005; 165: 1882-1888.
9. Leucht S, Wahlbeck K, Hamann J, Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003; 361: 1581-1589.
10. Kapur S, Seeman P. Does fast dissociation from the dopamine D2, receptor explain the action of atypical antipsychotics?: a new hypothesis. Am J Psychiatry 2001; 8158: 360-369.
11. Tarsy D, Baldessarini RJ, Tarazi FI. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs 2002; 16: 23-45.
12. Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 1999; 156: 286-293.
13. Miller LG, Jankovic J. Metoclopramide-induced movement disorders. Clinical fndings with a review of the literature. Arch Intern Med 1989; 149: 2486-2492.
14. Hirose G. Drug induced parkinsonism: a review. J Neurol 2006; 254 Suppl 3: 22-24.
15. Tinazzi M, Antonini A, Bovi T, Pasquin I, Steinmayr M, Moretto G, et al. Clinical and [123I]FP-CIT SPET imaging follow-up in patients with drug-induced parkinsonism. J Neurol 2009; 256: 910-915.
16. Yamamoto M, Ujike H, Ogawa N. Metoclopramide-induced parkinsonism. Clin Neuropharmacol 1987; 10: 287-289.
17. Reddymasu SC, Soykan I, McCallum RW. Domperidone: review of pharmacology and clinical applications in gastroenterology. Am J Gastroenterol 2007; 102: 2036-2045.
18. Franckx J, Noel P. Acute extrapyramidal dysfunction after domperidone administration. Report of a case. Helv Paediatr Acta 1984; 39: 285-288.
19. Gony M, Lapeyre-Mestre M, Montastruc JL; French Network of Regional Pharmacovigilance Centers. Risk of serious extrapyramidal symptoms in patients with Parkinson's disease receiving antidepressant drugs: a pharmacoepidemiologic study comparing serotonin reuptake inhibitors and other antidepressant drugs. Clin Neuropharmacol 2003; 26: 142-145.
20. Martinez-Martin P. Transient dyskinesia induced by clebopride. Mov Disord 1993; 8: 125-126.
21. Sempere A P, Duarte J, Palomares JM, Coria F, Clavería LE. Parkinsonism and tardive dyskinesia after chronic use of clebopride. Mov Disord 1994; 9: 114-115.
22. Martí-Massó J F, Poza JJ. Cinnarizine-induced parkinsonism: ten years later. Mov Disord 1998; 13: 453-456.
23. Brücke T, Wöber C, Podreka I, Wöber-Bingöl C, Asenbaum S, Aull S, et al. D2 receptor blockade by funarizine and cinnarizine explains extrapyramidal side efects. A SPECT study. J Cereb Blood Flow Metab 1995; 15: 513-518.
24. Meredith GE, Switzer RC, Napier TC. Short-term, D2 receptor blockade induces synaptic degeneration, reduces levels of tyrosine hydroxylase and brain-derived neurotrophic factor, and enhances D2-mediated fring in the ventral pallidum. Brain Res 2004; 995: 14-22.
25. Serrano A, Menendez J, Casarejos MJ, Solano RB, Gallego E, Sanchez M, et al. Effects of cinnarizine, a calcium antagonist that produces human parkinsonism, in parkin knock out mice. Neuropharmacology 2005; 49: 208-219.
26. Dick RS, Barold SS. Diltiazem-induced parkinsonism. Am J Med 1989; 87: 95-96.
27. Bondon-Guitton E, Perez-Lloret S, Bagheri H, Brefel C, Rascol O, Montastruc JL. Drug-Induced Parkinsonism: A Review of 17 Years' Experience in a Regional Pharmacovigilance Center in France. Mov Disord 2011; 26: 2226-2231.
28. Parker WD Jr, Boyson SJ, Parks JK. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann Neurol 1989; 26: 719-723.
29. Cabello CR, Tune JJ, Pakkenberg H, Pakkenberg B. Ageing of substantia nigra in humans: cell loss may be compensated by hypertrophy. Neuropathol Appl Neurobiol 2002; 28: 283-291.
30. Maneuf Y P, Mitchell IJ, Crossman AR, Brotchie JM. On the role of enkephalin cotransmission in the GABAergic striatal eferents to the globus pallidus. Exp Neurol 1994; 125: 65-71.
31. Easterford K, Clough P, Kellett M, Fallon K, Duncan S. Reversible parkinsonism with normal beta-CIT-SPECT in patients exposed to sodium valproate. Neurology 2004; 62: 1435-1437.
32. Benito-León J, Bermejo-Pareja F, Rodríguez J, Molina JA, Gabriel R, Morales JM, et al. Prevalence of PD and other types of parkinsonism in three elderly populations of central Spain. Mov Disord 2003; 18: 267-274.
33. Hardie RJ, Lees AJ. Neuroleptic-induced Parkinson's syndrome: clinical features and results of treatment with levodopa. J Neurol Neurosurg Psychiatry 1988; 51: 850-854.
34. Giladi N, Kao R, Fahn S. Freezing phenomenon in patients with parkinsonian syndromes. Mov Disord 1997; 12: 302-305.
35. Carlsson A. A paradigm shift in brain research. Science 2001; 294: 1021-1024.
36. Lewis S, Liddle J. Diagnosing non-parkinson's movement disorders. Practitioner 2012; 256: 21-24.
37. Arblaster LA, Lakie M, Mutch WJ, Semple M. A study of the early signs of drug induced parkinsonism. J Neurol Neurosurg Psychiatry 1993; 56: 301-303.
38. Marsálek M. Tardive drug-induced extrapyramidal syndromes. Pharmacopsychiatry 2000; 33 Suppl 1: 14-33.
39. Gershanik OS, Gómez Arévalo GJ. Typical and atypical neuroleptics. Handb Clin Neurol 2011; 100: 579-599.
40. Correll CU, Schenk EM. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry 2008; 21: 151-156.
41. Miller DD, Carof SN, Davis SM, Rosenheck RA, McEvoy J P, Saltz BL, et al. Extrapyramidal side-efects of antipsychotics in a randomised trial. Br J Psychiatry 2008; 193: 279-288.
42. Kasten M, Brüggemann N, König IR, Doerry K, Steinlechner S, Wenzel L, et al. Risk for antipsychotic-induced extrapyramidal symptoms: infuence of family history and genetic susceptibility. Psychopharmacology (Berl) 2011; 214: 729-736.
43. Levin T, Heresco-Levy U. Risperidone-induced rabbit syndrome: an unusual movement disorder caused by an atypical antipsychotic. Eur Neuropsychopharmacol 1999; 9: 137-139.
44. Hoy JS, Alexander B. Rabbit syndrome secondary to risperidone. Pharmacotherapy 2002; 22: 513-515.
45. Kim YD, Kim JS, Chung SW, Song IU, Yang DW, Hong YJ, et al. Cognitive dysfunction in drug induced parkinsonism (DIP). Arch Gerontol Geriatr 2011; 53: e222-e226.
46. Armon C, Shin C, Miller P, Carwile S, Brown E, Edinger JD, et al. Reversible parkinsonism and cognitive impairment with chronic valproate use. Neurology 1996; 47: 626-635.
47. Avorn J, Bohn RL, Mogun H, Gurwitz JH, Monane M, Everitt D, et al. Neuroleptic drug exposure and treatment of parkinsonism in the elderly: a case-control study. Am J Med 1995; 99: 48-54.
48. Uchida H, Mamo DC, Mulsant BH, Pollock BG, Kapur S. Increased antipsychotic sensitivity in elderly patients: evidence and mechanisms. J Clin Psychiatry 2009; 70: 397-405.
49. Metzer WS, Newton JE, Steele RW, Claybrook M, Paige SR, McMillan DE, et al. HLA antigens in drug-induced parkinsonism. Mov Disord 1989; 4: 121-128.
50. Mirsattari SM, Power C, Nath A. Parkinsonism with HIV infection. Mov Disord 1998; 13: 684-689.
51. Prophylactic use of anticholinergics in patients on long-term neuroleptic treatment. A consensus statement. World Health Organization heads of centres collaborating in WHO coordinated studies on biological aspects of mental illness. Br J Psychiatry 1990; 156: 412.
52. Rodríguez-Navarro JA, Casarejos MJ, Menéndez J, Solano RM, Rodal I, Gómez A, et al. Mortality, oxidative stress and tau accumulation during ageing in parkin null mice. J Neurochem 2007; 103: 98-114.
53. Fowler JS, Volkow ND, Wang GJ, Pappas N, Logan J, MacGregor R, et al. Neuropharmacological actions of cigarette smoke: brain monoamine oxidase B (MAO B) inhibition. J Addict Dis 1998; 17: 23-34.
54. Remington G, Mamo D, Labelle A, Reiss J, Shammi C, Mannaert E, et al. A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone. Am J Psychiatry 2006; 163: 396-401.
55. Mazurek MF, Savedia SM, Bobba RS, Garside S, Rosebush PI. Persistent loss of tyrosine hydroxylase immunoreactivity in the substantia nigra after neuroleptic withdrawal. J Neurol Neurosurg Psychiatry 1998; 64: 799-801.
56. Meredith GE, Switzer RC, Napier TC. Short-term, D2 receptor blockade induces synaptic degeneration, reduces levels of tyrosine hydroxylase and brain-derived neurotrophic factor, and enhances D2-mediated fring in the ventral pallidum. Brain Res 2004; 995: 14-22.
57. Solano RM, Casarejos MJ, Menéndez-Cuervo J, Rodriguez-Navarro JA, García de Yébenes J, Mena MA. Glial dysfunction in parkin null mice: effects of aging. J Neurosci 2008; 28: 598-611.
58. Subramanyam B, Rollema H, Woolf T, Castagnoli N. Identifcation of a potentially neurotoxic pyridinium metabolite of haloperidol in rats. Biochem Biophys Res Commun 1990; 166: 238-244.
59. Burn DJ, Sawle G V, Brooks DJ. Diferential diagnosis of Parkinson's disease, multiple system atrophy, and Steele-Richardson-Olszewski syndrome: discriminant analysis of striatal 18F-dopa PET data. Neurol Neurosurg Psychiatry 1994; 57: 278-284.
60. Muthane U, Yasha TC, Shankar SK. Low numbers and no loss of melanized nigral neurons with increasing age in normal human brains from India. Ann Neurol 1998; 43: 283-287.
61. Tolosa E, Coelho M, Gallardo M. DAT imaging in drug-induced and psychogenic parkinsonism. Mov Disord 2003; 18 Suppl 7: S28-S33.
62. Bocola V, Fabbrini G, Sollecito A, Paladini C, Martucci N. Neuroleptic induced parkinsonism: MRI fndings in relation to clinical course after withdrawal of neuroleptic drugs. J Neurol Neurosurg Psychiatry 1996; 60: 213-206.
63. Booij J, Speelman JD. The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism. Eur J Nucl Med 2001; 28: 266-272.
64. Bower JH, Dickson DW, Taylor L, Maraganore DM, Rocca WA. Clinical correlates of the pathology underlying parkinsonism: a population perspective. Mov Disord 2002; 17: 910-916.
65. Naito Y, Kuzuhara S. Essential points to differentiate various diseases causing parkinsonism. Nihon Rinsho 2004; 62: 1608-1616. Japanese
66. Saltz BL, Woerner MG, Robinson DG, Kane JM. Side effects of antipsychotic drugs. Avoiding and minimizing their impact in elderly patients. Postgrad Med 2000; 107: 169-172.
67. Fann WE, Lake CR. Amantadine versus trihexyphenidyl in the treatment of neuroleptic-induced parkinsonism. Am J Psychiatry 1976; 133: 940-943.
68. Bondon-Guitton E, Perez-Lloret S, Bagheri H, Brefel C, Rascol O, Montastruc JL. Drug-induced parkinsonism: a review of 17 years' experience in a regional pharmacovigilance center in France. Mov Disord 2011; 26: 2226-2231.
69. Lee PH, Kim JS, Shin DH, Yoon SN, Huh K. Cardiac 1231-MIBG scintigraphy in patients with drug induced parkinsonism. J Neurol Neurosurg Psychiatry 2006; 77: 372-374
70. Carlsson A, Carlsson ML. Adaptive properties and heterogeneity of dopamine D(2) receptors: pharmacological implications. Brain Res Rev 2008; 58: 374-378.
71. López-Sendón J, Mena MA, G de Yébenes J. Drug Induced Parkinsonism in the Elderly. Incidence, Management and Prevention. Drugs Aging 2012; 29: 105-118.